| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2017 | NBIX Neurocrine Biosciences Inc | Obrien Christopher Flint | Chief Medical Officer | Sell | 1,206 | $43.17 | $52,063.02 | -3.2% | |
| Feb 6, 2017 | MRK Merck & Co., Inc. | Weeks Wendell P62 | Director | Sell | 5,000 | $64.51 | $322,541.50 | -98.0% | |
| Feb 6, 2017 | LLY Eli Lilly & Co | Zulueta Alfonso G | SVP&Pres., Emerging Markets | Sell | 15,000 | $77.66 | $1,164,900.00 | -24.8% | |
| Feb 6, 2017 | NBIX Neurocrine Biosciences Inc | Coughlin Timothy P75 | Chief Financial Officer | Sell | 963 | $43.14 | $41,543.82 | -0.7% | |
| Feb 3, 2017 | MRK Merck & Co., Inc. | Cech Thomas R | Director | Sell | 5,000 | $63.42 | $317,099.50 | -98.0% | |
| Feb 3, 2017 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 1,375 | $42.57 | $58,533.75 | -1.2% | |
| Feb 3, 2017 | MRK Merck & Co., Inc. | Schechter Adam H | EVP &Pres-global Human Health | Sell | 36,335 | $63.73 | $2,315,698.59 | -100% | |
| Feb 3, 2017 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 1,375 | $42.56 | $58,520.00 | -1.2% | |
| Feb 3, 2017 | NBIX Neurocrine Biosciences Inc | Coughlin Timothy P75 | Chief Financial Officer | Sell | 1,500 | $42.55 | $63,825.00 | -1.1% | |
| Feb 3, 2017 | NBIX Neurocrine Biosciences Inc | Obrien Christopher Flint | Chief Medical Officer | Sell | 1,500 | $42.50 | $63,750.00 | -4.1% | |
| Feb 3, 2017 | MRK Merck & Co., Inc. | Wendell Peter C | Director | Sell | 15,000 | $63.69 | $955,405.50 | -93.8% | |
| Feb 3, 2017 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 3,125 | $42.55 | $132,968.75 | -1.2% | |
| Feb 3, 2017 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 1,375 | $42.57 | $58,533.75 | -2.2% | |
| Feb 3, 2017 | MRK Merck & Co., Inc. | Holston Michael J | EVP, General Counsel | Sell | 91,959 | $63.96 | $5,881,252.09 | -34.0% | |
| Feb 3, 2017 | LLY Eli Lilly & Co | Rice Derica W | Evp-global Services And CFO | Sell | 11,162 | $77.14 | $861,085.14 | -12.2% | |
| Feb 2, 2017 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 2,000 | $77.52 | $155,040.00 | -69.3% | |
| Feb 2, 2017 | LFCR Lifecore Biomedical, Inc. \de\ | Bitler Steven P | Vice President, Technology | Sell | 2,574 | $12.26 | $31,557.24 | -4.2% | |
| Feb 1, 2017 | JNJ Johnson & Johnson | Ullmann Michael H | Exec VP, General Counsel | Sell | 21,735 | $112.88 | $2,453,442.45 | -18.2% | |
| Feb 1, 2017 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 220,000 | $77.35 | $17,016,840.37 | - | |
| Feb 1, 2017 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,500 | $54.45 | $81,675.00 | -15.8% | |
| Feb 1, 2017 | NBIX Neurocrine Biosciences Inc | Rastetter William H48 | Director | Sell | 10,750 | $42.28 | $454,510.00 | -43.0% | |
| Jan 31, 2017 | LFCR Lifecore Biomedical, Inc. \de\ | Hiebert Larry D | Executive Vice President | Sell | 11,704 | $12.59 | $147,353.36 | -100% | |
| Jan 30, 2017 | CANN Trees Corp (colorado) | Kelsey Michael R. | 10% Owner | Sell | 1,290,090 | $2.75 | $3,547,747.50 | -51.6% | |
| Jan 25, 2017 | CANN Trees Corp (colorado) | Whitson Shelly | Principal Accounting Officer | Sell | 20,000 | $2.51 | $50,280.00 | -100% | |
| Jan 24, 2017 | DVAX Dynavax Technologies Corp | Janssen Robert71 | Vice President | Buy | 6,000 | $4.04 | $24,240.00 | +99.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.